Summer 2025
Sap Btp Intern
Posted on 6/16/2025
Legend Biotech
1,001-5,000 employees
Develops and commercializes cell therapies
No salary listed
Somerset County, NJ, USA
Hybrid
Intern must be able to commute to Somerset NJ site 3 days/week.
 Data & Analytics (2) |
|---|
| , |
Get referred to Legend Biotech
Find people who can refer or advise you
- SAP Datasphere certification or equivalent certifications in SAP data and analytics tools.
- Experience with cloud platforms such as AWS, Azure, or Google Cloud in conjunction with SAP solutions.
- Understanding of data governance frameworks and practices.
- Knowledge of machine learning and AI integration with SAP Datasphere.
- Currently in full-time pursuit of a Master’s or advanced level degree in Computer Science, Data Science, or related field with graduation date Dec 2025 or later.
- Bachelor’s degree in computer science, Information Technology, or a related field.
- 1+ years of experience working with SAP Datasphere (formerly SAP Data Warehouse Cloud) or similar data warehousing platforms.
- Strong knowledge of SAP analytics tools, including SAP Analytics Cloud (SAC).
- Proficiency in SQL, data modeling, and ETL/ELT processes.
- Familiarity with SAP BW, SAP HANA, or other SAP ecosystem solutions.
- Experience integrating SAP with third-party tools and platforms.
- Strong analytical and problem-solving skills with attention to detail.
- Excellent communication and interpersonal skills.
- Intern must be able to commute to Somerset NJ site 3 days /week.
- Design, implement, and maintain SAP Datasphere solutions to support enterprise data integration, management, and analytics.
- Collaborate with business and IT teams to gather requirements and deliver solutions tailored to business needs.
- Integrate SAP Datasphere with various SAP and non-SAP data sources, ensuring accurate and consistent data flow.
- Develop and optimize data models, data pipelines, and ETL processes within SAP Datasphere.
- Configure and optimize SAP Datasphere components, including Replication Flows, data targets, transformations, and jobs.
- Develop and maintain Spaces, Replication Flow, Transformation Flow, Data Access Control, Task Chain within SAP Datasphere.
- Monitor and troubleshoot system performance, data integration and transformation issues, ensuring high availability and reliability.
- Provide technical expertise in data governance, data security, and compliance within SAP Datasphere.
- Provide expertise on S/4HANA CDS views concepts to support data modelling and reporting needs.
- Support business users with training, best practices, and troubleshooting related to data visualization and reporting.
- Oversee Space management within SAP Datasphere, optimizing storage and performance.
- Stay updated on SAP Datasphere advancements and industry trends to propose innovative solutions.
Legend Biotech develops and commercializes cell therapies for serious diseases, including hematologic cancers and solid tumors, with a focus on personalized medicine. Its therapies, like CAR-T treatments, work by collecting a patient’s cells, engineering them to target cancer cells, expanding them, and reinfusing them into the patient. The company differentiates itself by using multiple technology platforms (technology-agnostic) and pursuing a broad pipeline, including exclusive global licenses for CAR-T therapies. Its goal is to bring effective, personalized cell therapies to market, improve outcomes for hard-to-treat cancers, and maintain transparent communication with investors while expanding globally.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Franklin Township, New Jersey
Founded
2014
Get referred to Legend Biotech
Find people who can refer or advise you
Simplify's Take
What believers are saying
- CARVYKTI sales reached $597 million in Q1 2026, up 62% year-over-year with expanding global markets.
- LB2501 in vivo CAR-T therapy achieved 100% response rate in lymphoma, simplifying patient access.
- The company expects adjusted profitability in 2026 with gross margins projected to exceed 50%.
What critics are saying
- Secondary malignancies in 5% of CARVYKTI patients may trigger FDA labeling changes threatening $2 billion sales.
- Severe neurotoxicities like ICANS could lead to black-box warnings reducing treatment site adoption and market expansion.
- Early mortality excess in CARTITUDE-4 may erode clinician confidence undermining first-line use strategy for CARVYKTI.
What makes Legend Biotech unique
- Legend Biotech is the largest standalone cell therapy company with technology-agnostic platforms.
- The company leads U.S. CAR-T trials for solid tumors via dominant-negative TGFβ receptor innovation.
- Legend Biotech operates an end-to-end model from discovery to global commercialization across 18 markets.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Sick Leave
Paid Holidays
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 2%Legend Biotech reported CARVYKTI net trade sales of approximately $555 million in Q4, up 66% year-over-year. Management said CARVYKTI reached profitability in 2025 and expects enterprise-wide profitability in 2026. The therapy is now available in 14 global markets across 294 treatment sites. Legend has installed manufacturing capacity for 10,000 doses, with plans to expand to 20,000 alongside Johnson & Johnson. Manufacturing success rates range from 97% to 99%. Clinical data show median progression-free survival of 50.4 months in triple-class-exposed patients with three prior lines of therapy. Approximately 65% of patients are now treated in the second-to-fourth-line setting, reflecting earlier use in the treatment course. Legend ended 2025 with $949 million in cash and recorded adjusted net income of $2.5 million in Q4.
Legend Biotech reported CARVYKTI net trade sales of approximately $555 million in the fourth quarter and $1.9 billion for the full year 2025, achieving franchise profitability. The company has treated over 10,000 patients with its CAR-T therapy and expanded availability to 294 sites across 14 markets worldwide. The company completed expansion of its Raritan facility, creating the largest cell therapy manufacturing site in the United States with capacity to support 10,000 patients annually. Legend Biotech also advanced its pipeline, opening a 31,000-square-foot R&D facility in Philadelphia and dosing the first patient for its in vivo candidates. As of 31 December 2025, Legend Biotech held $949 million in cash and cash equivalents, providing financial runway beyond 2026 when it expects to achieve company-wide operating profit.
Legend Biotech has raised $120 million in a Series C round led by Ribbit Capital, valuing the pre-revenue AI startup at $1.45 billion. Sequoia and Kleiner Perkins participated, alongside new backer Emerson Collective, bringing total capital raised to $295 million. Co-founded by Robinhood CEO Vlad Tenev, Harmonic develops "Mathematical Superintelligence" that eliminates AI hallucinations by requiring outputs in verifiable Lean4 programming code. Its Aristotle model achieved top performance at the International Mathematical Olympiad in July. Founded in 2023, the company currently offers Aristotle via free API to mathematicians and researchers. It plans future commercialisation targeting safety-critical sectors including aerospace, automotive and finance, where error-free logic is essential.
Biotech's next chapter: asset-centric deals and shifting alpha at JPM 2026. January 29, 2026 | After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation. Now that the sound and fury of the J.P. Morgan Healthcare Conference have subsided, investors are taking a step back to evaluate for 2026 the acquisition and capital environment, the buzzy therapeutic spaces and lingering risk factors. Biotech is emerging from a multiyear slump into a new cycle driven by fundamental progress and late-stage assets, said Roderick Wong, managing partner and chief investment officer at New York-based RTW Investments. Although JPM 2026 felt light on headline megadeals, record-setting M&A rumors before the conference around Revolution Medicines (reported to be in talks with Merck and AbbVie) and Abivax (with Eli Lilly speculation takeover) underscored strong demand for high quality, late-stage development assets, Wong said. Actual announced deals (e.g., Eli Lilly - Ventyx Biosciences, GlaxoSmithKline - RAPT Therapeutics, Boston Scientific - Penumbra) reinforced that asset-centric transactions are with clear blockbuster or strategic potential are the most interesting, Wong said. From RTW's vantage point and reinforced by several VC conversations on the sidelines of JPM26, asset-focused companies remain more attractive than pure platform or technology plays in the current environment. Hot therapeutic investment spaces. Key disease areas of focus include oncology (pancreatic, breast, bladder), where several programs could reset standards of care and address major unmet needs, noted Stephanie Sirota, partner and chief business officer at RTW. Obesity is another major theme, with anticipation around the first true small-molecule pill from Eli Lilly and a next wave of novel mechanisms, Wong said. One of RTW's portfolio companies, Corxel, announced on January 23 a $287 million Series D fundraising. Neuroscience/CNS has seen a sharp sentiment shift, with investors leaning back into space after years of limited innovation, Wong and Sirota agreed. Their comments echo those heard on the sidelines of JPM26; that advances in biomarkers, brain mapping and AI, as well as a rapidly aging population, support investment in the space. Psychedelics exemplify a potential paradigm shift in depression treatment modality, Wong said, with Compass Pathways' Phase III data and a possible near-term launch supporting nondaily, episodic treatment models. The cultural and medical shift in psychedelic therapeutic is one of the topics explored in the RTW's latest book "Innovation is the Best Medicine." FDA remains a risk factor. The degree of policy risk for the biopharma sector has declined significantly since the start of the Trump administration last year, Wong said. At the time, major uncertainties surrounded tariffs, manufacturing reshoring and Most Favored Nations drug pricing negotiations. What has evolved are reasonable resolutions that have been neutral to modestly negative rather than worstcase scenarios, he added. There have been many discussions around the chaotic year at the FDA in 2025, including a revolving door of senior staff members. The main remaining structural risk, Wong said, is FDA behavior in "edge cases," particularly in rare diseases and emerging modalities like gene and cell therapies, using nontraditional trial designs, surrogate endpoints or single arm studies. Last year's players in this space saw negative feedback or rejection, discussed in greater depth in the RTW book. RTW is responding by being more conservative around such edge case programs, which it expects will depress capital flows into some rare disease and early modality assets. Alpha stacking model. The firm frames its investment process as "alpha stacking:" starting with rigorous fundamental equity analysis (science underwriting plus commercial forecasting) and layering on multiple, evolving sources of information and assessment, Sirota said. This includes collecting information on policy, considering transactional and operational models, as well as what is compelling from a buyer perspective. The firm has built deep therapeutic specialization plus functional expertise (e.g., IP, geography such as China) to move beyond headline-driven views of risk and opportunity. RTW has also invested internally in data science, automation and AI to enhance its research process, they agreed. Ultimately, investment is always evolving, Wong said. He noted that a scientific background at one was the advantage - an alpha - one had when investing, but that's become understood. Rather, alpha stacking is now about intentionally trying to understand where the advantages lie and staying on top of these evolving factors. In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW's Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how "alpha stacking" shapes their investment edge in an age of chronic uncertainty. January 29, 2026
On August 18, 2025, Legend Biotech Corporation announced the appointment of Carlos Santos as the Company's Chief Financial Officer ("CFO").